Company: WHWK
Filing Date: 2025-03-26
Form Type: 8-K
Source: 0001193125-25-063253
Chunk: 1

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-26
Form: 8-K
Item: Item 9.01
Chunk 1
---
Item 9.01.      Financial Statements and Exhibits.  

(b) The Company intends to file the pro forma financial information required by Item 9.01(b) as part of an amendment to this Current Report on Form 8-K no later than four business days after the closing of the Divestiture.

(d) Exhibits

  Exhibit      Description                                                                                                                                                                                           
                                                                                                                                                                                                                     
  Number                                                                                                                                                                                                             
  2.1†         Stock Purchase Agreement, dated December 19, 2024, among Aadi Bioscience, Inc., KAKEN INVESTMENTS INC., KAKEN PHARMACEUTICAL CO., LTD., and Aadi Subsidiary, Inc. (incorporated by reference to E...  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  104          Cover Page Interactive Data File (embedded within the Inline XBRL document).                                                                                                                          

  Schedules and exhibits to this Exhibit omitted pursuant to Regulation S-K Item 601(b)(2). The Registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC up...  

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                      WHITEHAWK THERAPEUTICS, INC.  
  March 26, 2025      /s/ Scott Giacobello          
                      Scott Giacobello              
                      Chief Financial Officer